Other Hematological Diseases

Amyloidosis

Newly Diagnosed

HEMMY0036
Cardiac Amyloid
Reaching for
Extended Survival:
Phase III
Double-Blind Study
to Evaluate Efficacy
& Safety of
CAEL-101 & Plasma
Cell Dyscrasia
Treatment vs
Placebo & Plasma
Cell Dyscrasia
Treatment in Plasma
Cell Dyscrasia
Treatment-Naive
Patients of Mayo
Stage IIIa AL
Amyloidosis

PI: Liedtke
Sponsor: Alexion Pharmaceuticals, Inc.

Relapsed

HEMMY0037
Daratumumab
Pomalidomide &
Dexamethasone
(DPo) in Relapsed /
Refractory Light
Chain Amyloidosis
Patients Previously
Exposed to
Daratumumab

PI: Liedtke
Sponsor: Weill
Cornell Medical
College

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu